EMEA-001407-PIP03-20
Key facts
Invented name |
Opdivo
|
Active substance |
nivolumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0280/2020
|
PIP number |
EMEA-001407-PIP03-20
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of all conditions in the category of malignant neoplasms (except central nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms other than Hodgkin lymphoma)
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|